Navigation Links
Hard To Treat Diseases (HTDS) to Retire Regulation D 504 Offering
Date:9/3/2009

SHENZHEN, China, Sept. 3 /PRNewswire-FirstCall/ - Hard to Treat Diseases (the "Company") (HTDS.PK) announced today that it has closed its Regulation D, Rule 504 offering and is no longer selling shares of its common stock to accredited investors. A Form D will be filed with the Securities and Exchange Commission shortly, disclosing that the company has raised $990,000 in the offering over the past twelve months. The limit to any such offering is $1 million per year.

HTDS is a holding company for China-based Shenzhen Mellow Hope Pharm Industrial Co., Ltd. Mellow Hope is the biggest exporter of biological vaccines in China. Based on the cooperation with Institutes of Medical Biology and pharmaceutical manufacturers, Mellow Hope provides a wide range of vaccines with high quality, safety and efficacy. HTDS' other controlling interests include an East European (Serbian) medical company, Slavica Biochem, whose experts are performing cutting edge research in the field of neurological impairments in Multiple Sclerosis (MS) and Traumatic Brain Injury (TBI). The primary focus of Slavica Biochem is to investigate novel therapeutic approaches in treatment of these disorders of the CNS (central nervous system), as well as to enhance and modify existing approved drugs such as VIRAZOLE(R).

Closing the 504 offering brings to an end the issuer's recent use of equity in financing operations. With the new increased pool of credit the issuer intends to cover a majority of its upfront costs associated with its increasing contract demands. The issuer is looking forward to releasing quite a bit of new information over the next few weeks, including the finalized contracts as well as outlining its revised business plan to shareholders and potential investors. The revised business plan under consideration includes an anti-aging and cancer treatment project through nutritional supplementation.

The equity in financing has also opened up an opportunity for HTDS management to explore a possible lucrative joint venture project with a North American-based pharmaceutical company.

The issuer does not foresee the need or reason to disturb its current share structure, through dilution or otherwise. Management now intends to recalibrate its focus to its previously announced plans of addressing its share price, and matters that will increase its shareholder value. The issuer remains very optimistic that a 0.03 cent price per share is within its reach.

The issuer intends to furnish its shareholders with forward guidance shortly.

Safe Harbor Statement:

Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo@htdsmedical.com; For any corporate matters, please contact www.minamargroup.com/helpdesk


'/>"/>
SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Reportlinker Adds U.S. Markets for Addiction and Substance Abuse Treatment Report
2. Patients pretreatment quality of life can predict overall lung cancer survival
3. Twitter Users Can Follow in Real Time as Local Woman Receives Cyberknife Treatment for Lung Cancer
4. Forterus Inc. Treatment Centers Showing Consistent, Sustainable Growth; CEO Paul Howarth Interviewed
5. Potential Breakthrough Cancer Treatment Now Available From Vascular Designs
6. Relapse of Infections is the Most Challenging Aspect of Treating Clostridium Difficile Infections in the Hospital Setting
7. Two Treatments Equally Effective for Chronic Pelvic Pain
8. St. Lukes Episcopal Hospital First in Houston to Offer Revolutionary Noninvasive Tumor Treatment
9. 2 Independent Studies Released on the Effectiveness of Prostate Cancer Treatment
10. National guideline released for the treatment of hoarseness
11. New treatment in sight for ovarian cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... January 20, 2017 , ... Doctor C LLC, a company ... January ECRM trade show to continue the marketing and distribution of its product, The ... for providing 400 percent better absorption than traditional vitamin C supplements. At the trade ...
(Date:1/20/2017)... ... 20, 2017 , ... Lice Troopers, the lice removal company based in South ... since the holiday season. , “It happens every year around this time,” says ... taking photos, which is the head-to-head gateway that lice need to spread.” , As ...
(Date:1/20/2017)... ... January 20, 2017 , ... International Protein, a company based out ... announced it attended the January ECRM trade show in Hilton Head, SC. , ... was determined to create a line of products that would elevate her fitness regime. ...
(Date:1/20/2017)... Viejo, California (PRWEB) , ... January 20, 2017 , ... ... easy to use inside of Final Cut Pro X," said Christina Austin - CEO ... on the RED Dragon. Utilizing the Dragon Sensor,TransFlare 4K Mystique lens flare and light ...
(Date:1/20/2017)... ... January 20, 2017 , ... “Mary Magdalene: Grace is Greater than Sin”: ... woman who witnessed Jesus Christ firsthand. “Mary Magdalene: Grace is Greater than Sin” is ... as an educator interacting with countless women who had little knowledge of the female ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... Conference Call and Webcast to Follow Vanda ... will release results for the fourth quarter of 2016 on Wednesday, ... ... at 4:30 PM ET on Wednesday, February 15, 2017, during which ... results and other corporate activities. To participate in the conference call, ...
(Date:1/19/2017)... -- Stealth BioTherapeutics Inc. ( Stealth ), a clinical-stage biopharmaceutical ... new additions to its senior leadership team: W. ... Daniel Geffken as interim Chief Financial Officer. ... Pharm.D. has been promoted to Chief Clinical Development Officer. ... and Daniel to our management team, as both will ...
(Date:1/19/2017)...  Abaxis, Inc. (NasdaqGS: ABAX ), a ... consumables for the medical and veterinary markets worldwide, has ... for the third quarter fiscal year 2017, ended December ... ET on Thursday, January 26, 2017.  The Company will ... 2017 after the market closes on Thursday, January 26, ...
Breaking Medicine Technology: